Phase II Feasibility and Biomarker Study of Neoadjuvant Trastuzumab and Pertuzumab With Chemoradiotherapy for Resectable Human Epidermal Growth Factor Receptor 2–Positive Esophageal Adenocarcinoma: TRAP Study

PURPOSE: Approximately 15% to 43% of esophageal adenocarcinomas (EACs) are human epidermal growth factor receptor 2 (HER2) positive. Because dual-agent HER2 blockade demonstrated a survival benefit in breast cancer, we conducted a phase II feasibility study of trastuzumab and pertuzumab added to neo...

وصف كامل

محفوظ في:
التفاصيل البيبلوغرافية
الحاوية / القاعدة:J Clin Oncol
المؤلفون الرئيسيون: Stroes, Charlotte I., Schokker, Sandor, Creemers, Aafke, Molenaar, Remco J., Hulshof, Maarten C.C.M., van der Woude, Stephanie O., Bennink, Roel J., Mathôt, Ron A.A., Krishnadath, Kausilia K., Punt, Cornelis J.A., Verhoeven, Rob H.A., van Oijen, Martijn G.H., Creemers, Geert-Jan, Nieuwenhuijzen, Grard A.P., van der Sangen, Maurice J.C., Beerepoot, Laurens V., Heisterkamp, Joos, Los, Maartje, Slingerland, Marije, Cats, Annemieke, Hospers, Geke A.P., Bijlsma, Maarten F., van Berge Henegouwen, Mark I., Meijer, Sybren L., van Laarhoven, Hanneke W.M.
التنسيق: Artigo
اللغة:Inglês
منشور في: American Society of Clinical Oncology 2020
الموضوعات:
ORIGINAL REPORTS
الوصول للمادة أونلاين:https://ncbi.nlm.nih.gov/pmc/articles/PMC7007286/
https://ncbi.nlm.nih.gov/pubmed/31809243
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1200/JCO.19.01814
الوسوم: إضافة وسم
لا توجد وسوم, كن أول من يضع وسما على هذه التسجيلة!

مواد مشابهة